Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in
the world. The emerging field of cardio-oncology has revealed that these seemingly …

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to
cancer patients. With the prolongation of survival of cancer patients and increased clinical …

Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has
risen to become a prominent clinical challenge. This has led to the growth of the burgeoning …

Myocardial protection against ischemia/reperfusion injury (IRI) is mediated by various
ligands, activating different cellular signaling cascades. These include classical cytosolic …

In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of
life. With improvements in early diagnosis and treatment, the number of cancer survivors …

Sažetak In the year 2021, the universal definition and classification of heart failure (HF) was
published that defines HF as a clinical syndrome with symptoms and/or signs caused by a …

Aims The association between heart failure (HF) patients and the incidence of cancer is not
well understood, with conflicting results to date. The aim of this meta-analysis was to …

Cardiovascular disease (CVD) caused by anti-cancer drug-induced cardiotoxicity is now the
second leading cause of mortality among cancer survivors. It is necessary to establish …

Background Heart failure (HF) is the most common outcome of cardiovascular disease, and
an increasing number of patients with heart failure die from noncardiac causes, such as …

With the increase of aging population and prevalence of obesity, the incidence of
cardiovascular disease (CVD) and cancer has also presented an increasing tendency …